Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes

Abstract

Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates glucose-dependent insulin secretion and can modify the level of inflammatory biomarkers.

Keywords

• glucagon-like peptide 1 (glp-1)
• liraglutide
• diabetes
• obesity
• nf-kb
• sirt1
• mediators of inflammation